Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature

Ongoren S., Eskazan A. E., Suzan V., Savci S., Ozunal I. E., Berk S., ...Daha Fazla

HEMATOLOGY, cilt.23, sa.4, ss.212-220, 2018 (SCI-Expanded) identifier identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 23 Sayı: 4
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1080/10245332.2017.1385193
  • Dergi Adı: HEMATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.212-220
  • Anahtar Kelimeler: Chronic myeloid leukemia, dasatinib, imatinib, nilotinib, third-line treatment, tyrosine kinase inhibitor, CHROMOSOME-POSITIVE LEUKEMIAS, CHRONIC MYELOGENOUS LEUKEMIA, PATIENTS RECEIVING IMATINIB, CHRONIC-PHASE, EUROPEAN LEUKEMIANET, FOLLOW-UP, THERAPY, FAILURE, RESISTANCE, RECOMMENDATIONS
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

Objectives: Newer tyrosine kinase inhibitors (TKIs) (bosutinib, ponatinib) and allogeneic hematopoietic stem cell transplantation (allo-HSCT) can be utilized as a salvage therapy in patients with chronic myeloid leukemia (CML) who failed two lines (imatinib -> nilotinib or imatinib -> dasatinib) of TKI therapy. However, these TKIs are not available in many countries and not all patients can undergo allo-HSCT.